solcitinib   Click here for help

GtoPdb Ligand ID: 9697

Synonyms: compound 1 [WO2010149771] | GLPG-0778 | GLPG0778 | GSK2586184
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Solcitinib is a Janus kinase 1 (JAK1)-selective inhibitor, with anti-inflammatory activity [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 79.6
Molecular weight 389.19
XLogP 3.08
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(C1CC1)Nc1nn2c(n1)cccc2c1ccc(cc1)C(=O)N1CC(C1)(C)C
Isomeric SMILES O=C(C1CC1)Nc1nn2c(n1)cccc2c1ccc(cc1)C(=O)N1CC(C1)(C)C
InChI InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)
InChI Key MPYACSQFXVMWNO-UHFFFAOYSA-N
References
1. Blanc J. (2010)
Novel compound useful for the treatment of degenerative and inflammatory diseases.
Patent number: WO2010149771. Assignee: Galapagos Nv, Menet, Christel Jeanne Marie. Priority date: 26/06/2009. Publication date: 29/12/2010.
2. Kahl L, Patel J, Layton M, Binks M, Hicks K, Leon G, Hachulla E, Machado D, Staumont-Sallé D, Dickson M et al.. (2016)
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
Lupus, 25 (13): 1420-1430. [PMID:27055521]
3. Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, Watson J, Wilson P, Simeoni M, Schifano LA et al.. (2016)
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.
Br J Dermatol, 174 (5): 985-95. [PMID:26785220]